KR100513162B1 - The method of manufacturing of the extract from the Platycodon grandiflorum A. DC - Google Patents
The method of manufacturing of the extract from the Platycodon grandiflorum A. DC Download PDFInfo
- Publication number
- KR100513162B1 KR100513162B1 KR10-2001-0076224A KR20010076224A KR100513162B1 KR 100513162 B1 KR100513162 B1 KR 100513162B1 KR 20010076224 A KR20010076224 A KR 20010076224A KR 100513162 B1 KR100513162 B1 KR 100513162B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- gilyeong
- ethanol
- irradiated
- present
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 239000000284 extract Substances 0.000 title claims description 41
- 244000274050 Platycodon grandiflorum Species 0.000 title description 2
- 235000006753 Platycodon grandiflorum Nutrition 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000919 ceramic Substances 0.000 claims abstract description 14
- 238000010438 heat treatment Methods 0.000 claims abstract description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910001873 dinitrogen Inorganic materials 0.000 claims abstract description 10
- 238000005507 spraying Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 241000332371 Abutilon x hybridum Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- -1 analgesic Substances 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 150000003505 terpenes Chemical group 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- ITYGLICZKGWOPA-UHFFFAOYSA-N (2R,3R,4S,5S,6R)-2-[[(3S,5S,9R,10S,13R,14R,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Natural products C1CC2(C)C3CCC4(C)C(C(C)C=CC(CC)C(C)C)CCC4C3=CCC2CC1OC1OC(CO)C(O)C(O)C1O ITYGLICZKGWOPA-UHFFFAOYSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ACCRBMDJCPPJDX-UHFFFAOYSA-N Methyl 3-hydroxyhexanoate Chemical compound CCCC(O)CC(=O)OC ACCRBMDJCPPJDX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- ITYGLICZKGWOPA-PYUVDJBBSA-N alpha-spinasterol glucoside Natural products CC[C@H](C=C[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C ITYGLICZKGWOPA-PYUVDJBBSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229930188557 apratoxin Natural products 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003971 tillage Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/12—Electrical treatment, e.g. electrolysis, electrical field treatment, with or without heating effect
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 건조 길경을 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리한 후 에탄올 중에서 초고주파 처리하여 제균여과기로 여과하여 고함량의 조사포닌이 함유된 길경 추출물의 제조방법에 관한 것이다.In the present invention, the dried pathoscope is heat treated at 110 to 130 ° C while spraying with nitrogen gas in a heating dryer made of ceramic, and then treated with ultra-high frequency in ethanol and filtered with a sterile filter to obtain a high content of irradiated pongonine. It relates to a manufacturing method of.
Description
본 발명은 길경 추출물의 제조방법에 관한 것으로, 더욱 상세하게는 건조 길경을 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리한 후 에탄올 중에서 초고주파 처리하여 제균여과기로 여과하여 길경 추출물의 제조방법에 관한 것이다.The present invention relates to a method for producing a gilyeong extract, and more particularly, a sterile filtration filter by heating at 110 to 130 ℃ while spraying the dried gilyeong using a nitrogen gas in a heating dryer made of ceramics in ethanol It relates to a method for producing Giltyeong extract by filtration.
길경(도라지 Platycodon grandiflorum A. DC)은 배농, 거담, 기관지염, 천식, 소염 등의 호흡기계질환에 사용되어온 생약제로서 길경이 배합되어 있는 한방 처방은 동의보감에 273건, 방학합편에 49건이 수록되어 있을 정도로 다양한 약리작용을 가지고 있는 것으로 알려져 있다.Gilkyung (Platycodon grandiflorum A. DC) is a herbal medicine that has been used for respiratory diseases such as drainage, expectoration, bronchitis, asthma, and anti-inflammatory. It is known to have a variety of pharmacological action.
도라지의 주요 약리성분은 테르펜계 사포닌(프레티코틴 A, C, D, D6, 폴리갈리신 D, D2 등 18종)으로서 뿌리의 약 2%를 차지하고 있다. 동물실험에서 테르펜계 사포닌은 용혈, 국소자극, 진해, 거담작용, 중추신경억제작용(진정, 진통, 해열효과), 급ㆍ만성 염증에 대한 항염증작용, 항알레르기, 항궤양 및 위액분비억제작용, 혈관을 확장하여 혈압을 낮추는 항콜린작용, 혈당강하작용, 콜레스테롤 대사개선작용 등이 있는 것으로 밝혀졌다[Igarashi, K., Sogoigaku, 3, 1(1951) 및 이은방, 생약학회지, 5, 49(1974)]. 또한 도라지의 약리성분으로서 알파-스피나스테롤, 스티그마스트-7-엔올, 알파-스피나스테롤글루코시드 등과 같은 스테로이드계 화합물과 이눌린, 플레티코디딘, 베튤린과 같은 다당류도 단리되었다.The major pharmacological component of bellflower is terpene-based saponins (prestige A, C, D, D 6 , polyglycine D, D 2 and 18 species), which account for about 2% of the roots. In animal experiments, terpene-based saponins are hemolytic, localized, antitussive, expectorant, central nervous inhibitory (sedative, analgesic, antipyretic), anti-inflammatory against acute and chronic inflammation, anti-allergic, anti-ulcer and gastric secretion , Anticholinergic to lower blood pressure by expanding blood vessels, lowering blood sugar, improving cholesterol metabolism [Igarashi, K., Sogoigaku, 3, 1 (1951) and Lee Eun-bang, Journal of Pharmacognosy, 5, 49 (1974) )]. In addition, as pharmacological components of the bellflower, steroidal compounds such as alpha-spinasterol, stigmas-7-enol, alpha-spinasterol glucoside and the like and polysaccharides such as inulin, platicodidine and betulin were also isolated.
이외에도 도라지의 열수 및 에탄올 추출물은 곰팡이의 아프라톡신을 억제하며 이눌린의 분획은 식균작용을 가지며 과당중합체인 이눌린은 고형암과 복수암에 대한 항종양효능이 있다고 알려져 있다. In addition, the hot water and ethanol extract of bellflower inhibit the fungal apratoxin, and the fraction of inulin has phagocytosis, and the inulin, a fructose polymer, is known to have antitumor effect against solid and ascites cancers.
현재 한국, 중국, 일본 등에서 도라지가 함유된 한방제제는 30여종이 시판되고 있는데, 오약순기산, 통기환, 순기원 등은 중풍, 관절염 등의 치료제로서 안심원과 천왕보심단은 고혈압, 뇌질환 등의 치료제로서 자모연조 엑기스는 기관지염, 폐결핵, 늑막염 등의 치료제로서 만옥단은 고혈압, 동맥경화, 당뇨병 등의 치료제로서 각각 이용되고 있다. 이외에 길경을 함유한 한방제제는 천식, 거담, 배농, 진해 등과 같은 기관지 관련 질병에 사용되고 있다.Currently, about 30 kinds of Korean herbal medicines containing bellflower are sold in Korea, China, Japan, etc., and five drugs such as five-Yam Soon Ki-san, Tong-hwan-hwan, and Soon-gi-won are treatments for stroke, arthritis, etc. As a therapeutic agent, Jamomile extract is used as a therapeutic agent for bronchitis, pulmonary tuberculosis, pleurisy, and the like. Manokdan is used as a therapeutic agent for hypertension, arteriosclerosis, and diabetes, respectively. In addition, herbal medicines containing Gilkyung are used for bronchial diseases such as asthma, expectoration, drainage, and Jinhae.
본 발명자들은 건조 길경을 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리하는 경우 그 길경 추출액에 사포닌의 함량이 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리하지 아니한 경우에 비하여 사포닌의 함량이 2배 이상 함유되어 있다는 것을 발명하여 새로운 길경 추출물의 제조방법을 개발하기에 이르렀다.The present inventors use nitrogen gas in a heat dryer made of ceramic with saponin content in the case of heat treatment at 110-130 ° C. while spraying the dried road mirror using nitrogen gas in a heat dryer made of ceramic. Invented that the saponin content is more than two times as compared to the case of not heating at 110 ~ 130 ℃ while spraying to develop a new method for producing a gilyeong extract.
따라서 본 발명은 사포닌의 함량이 다량 함유되어 있는 길경의 추출방법을 제공함에 있다.Therefore, the present invention is to provide a method for extracting Gilyeong which contains a large amount of saponin.
본 발명의 상기 목적은 건조 길경을 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리한 후 에탄올 중에서 초고주파 처리하여 제균여과기로 여과하여 길경 추출물의 제조하여 달성되었다.The above object of the present invention was achieved by heating at 110-130 ° C. while spraying a dry pathoscope using a nitrogen gas in a heating dryer made of ceramic, followed by ultra-high frequency treatment in ethanol, and filtering it with a sterile filter to prepare a pathogen extract. .
이하, 본 발명의 구성 및 작용을 설명한다. Hereinafter, the configuration and operation of the present invention.
본 발명은 건조 길경을 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리한 후 에탄올 중에서 초고주파 처리하여 제균여과기로 여과하여 고함량의 조사포닌이 함유된 길경 추출물의 제조방법에 관한 것이다.In the present invention, the dried pathoscope is heat treated at 110 to 130 ° C while spraying with nitrogen gas in a heating dryer made of ceramic, and then treated with ultra-high frequency in ethanol and filtered with a sterile filter to obtain a high content of irradiated pongonine. It relates to a manufacturing method of.
본 발명은 (1)길경을 세라믹 가열 건조기 내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리하는 단계; (2)상기 가열 처리된 건조 길경을 에탄올 중에서 초고주파 처리하는 단계; 및 (3)상기 처리된 길경 추출물을 제균여과기로 여과하는 단계를 포함함을 특징으로 한다.The present invention comprises the steps of (1) heat treatment at 110 ~ 130 ℃ while spraying the path diameter using nitrogen gas in a ceramic heat dryer; (2) ultra-high frequency treatment of the heat-treated dry pathoscope in ethanol; And (3) characterized in that it comprises the step of filtering the treated gilyeong extract with a sterile filter.
길경은 야생에서 채취할 수 있으나 본 발명에서는 경동시장에서 구입하여 사용하였다. 길경의 추출물은 다음과 같은 특성에 의해 확인할 수 있다. 길경의 추출물은 혈당, 혈청, 간장 등의 지질개선효과가 우수하여 당뇨병 치료에도 유용하다. 길경의 추출물은 용매의 극성에 따라서 분획하여 면역증강기능을 조사하여 보면 수용액층에서 우수한 효과가 나타난다. 본 발명의 길경 추출물은 약리활성을 이용한 건강식품 및 약제에 사용한다. 건강식품이나 약제로 제공될 수 있는 본 발명의 길경 추출물은 이 분야에서 통상적으로 사용되는 방법에 따라서 처리된다. 길경 추출물은 통상 열수추출물 또는 유기용매추출물을 들 수 있으며 이러한 추출물들은 단독으로 사용될 수 있으며 생약제를 첨가하여 제조될 수도 있다. Gilkyung can be harvested from the wild, but in the present invention, it was purchased and used in Gyeongdong market. Extract of Gilgil can be confirmed by the following characteristics. The extract of Gil-Kil is useful for treating diabetes because of its excellent lipid-improving effect on blood sugar, serum, and liver. The extract of Gil-Gyeong is divided according to the polarity of the solvent and investigated the immune enhancing function. Gilkyung extract of the present invention is used in health foods and drugs using pharmacological activity. The gilyeong extract of the present invention, which can be provided as a health food or a medicament, is treated according to methods commonly used in the art. Gilkyung extract may include a hot water extract or an organic solvent extract, these extracts may be used alone or may be prepared by adding a herbal medicine.
일반적으로 길경의 열수추출물은 길경의 분말에 약 5 내지 10배의 물을 첨가하고 90 내지 100℃ 온도에서 4 내지 6시간 동안 2회 추출하여 얻은 여과액을 사용한다. 길경의 열수추출물은 허용가능한 생약제 또는 생약제 추출물을 선택적으로 첨가하여 제조될 수 있다.In general, the hot water extract of Gilyeong using filtrate obtained by adding about 5 to 10 times water to Gilyeong powder and extracting twice at 90-100 ° C. for 4-6 hours. The hot water extract of Kilkyung may be prepared by selectively adding an acceptable herbal medicine or herbal extract.
길경을 유기용매로 추출하는 경우에는 길경 분말에 약 3배의 유기용매를 첨가하고 실온에서 2회 추출하여 얻어진 여과액을 감압농축하여 추출물을 얻는다. 상기 유기용매로는 알코올이 사용될 수 있으며 메탄올, 에탄올이 바람직하다. In the case of extracting Gilkyung with an organic solvent, about three times the organic solvent is added to Gilgil powder, and the filtrate obtained by extracting twice at room temperature is concentrated under reduced pressure to obtain an extract. Alcohol may be used as the organic solvent, and methanol and ethanol are preferable.
본 발명의 길경 추출물은 식품위생법상 또는 약제학적으로 허용가능한 보형제를 이용하는 공지의 방법으로 건강보조식품화 또는 제제화로 될 수 있다.The gilyeong extract of the present invention may be a dietary supplement or formulated by a known method using a food hygiene method or a pharmaceutically acceptable prosthesis.
본 발명의 길경 추출물의 제조방법의 바람직한 공정도는 도 1에 도시된 바와 같다. 본 발명의 길경 추출물의 제조방법은 건조길경을 세라믹건조기 내에서 110 내지 130℃ 온도에서 처리하는 것이 바람직하다. 건조길경을 세라믹건조기 내에서 110℃이하로 처리하는 경우 길경유동엑스 추출물에 함유된 조사포닌의 함량은 현저하게 낮았으며 건조길경을 세라믹건조기 내에서 130℃이상으로 처리하는 경우에도 길경유동엑스 추출물에 함유된 조사포닌의 함량은 현저하게 낮았다. 또한 본 발명의 길경 추출물의 제조방법은 건조길경을 에탄올 중에서 초고주파로 처리하는 것이 바람직하다. 건조길경을 에탄올 중에서 초고주파로 처리하는 경우 길경유동엑스 추출물에 함유된 조사포닌의 함량은 현저하게 높았으며 건조길경을 에탄올 중에서 초고주파로 처리하지 않은 경우에는 길경유동엑스 추출물에 함유된 조사포닌의 함량은 현저하게 낮았다. Preferred process diagram of the preparation method of the gilyeong extract of the present invention is as shown in FIG. In the method for preparing the Gilyeong extract of the present invention, it is preferable to treat the dried Gilkyung at a temperature of 110 to 130 ° C. in a ceramic dryer. When the drying path length was treated at 110 ℃ or lower in the ceramic dryer, the content of irradiated ponponin contained in the road light flow extract was remarkably low, and even when the drying length was treated at 130 ℃ or higher in the ceramic dryer, The content of irradiated phononine was markedly low. In addition, the method of preparing the Gilyeong extract of the present invention is preferred to treat the dried Gilyeong in ultra-high frequency in ethanol. In the case of treatment of dried road tillage with ultra-high frequency in ethanol, the content of the irradiated saponin was significantly higher. Significantly lower.
이하, 본 발명의 구체적인 구성과 작용을 실시예 및 실험예를 들어 보다 상세히 설명한다. 그러나, 본 발명의 권리범위가 이들 실시예 및 제조예에만 한정되는 것은 아니다.Hereinafter, the specific configuration and operation of the present invention will be described in more detail with examples and experimental examples. However, the scope of the present invention is not limited only to these examples and production examples.
실시예 1Example 1
대한약전에 따른 길경유동엑스의 제조Preparation of Gilkyung Fluid X in accordance with the Korean Pharmacopoeia
길경의 조말 11Kg을 25 v/v(%) 에탄올 80ℓ중에 넣고 실온의 냉암소에서 7일간 방치한 후 여과하여 길경 유동엑스 추출물 26ℓ를 수득한다.11 Kg of gilyeong powder was added to 80 l of 25 v / v (%) ethanol, and left in a dark room at room temperature for 7 days, followed by filtration to obtain 26 l of gilyeong flow extract.
실시예 2Example 2
식품공전에 따른 길경 유동엑스 추출물에 대한 조사포닌의 함량 분석Analysis of Irradiated Phononin Contents on the Extracts of Gilkyung Fluid Extracts According to Food Code
실시예 1에서 수득한 길경 유동엑스 추출물 1g을 정확하게 달아 삼각플라스크에 넣고 물 60㎖에 녹여 분액깔때기에 옮기고 에테르 60㎖로 씻은 다음 물층을 물포화 부탄올 60㎖로 3회 추출한다. 추출액을 모두 합쳐서 물 50㎖로 씻는다. 물포화 부탄올층을 미리 항양으로 한 농축플라스크에 옮겨 감압농축한 후 105℃에서 20분간 건조하고 다시 데시케이트에서 30분간 식혀 무게를 달아 하기식에 따라서 조사포닌의 양을 구한다. 상기 방법에 따라서 측정한 조사포닌의 양은 1.33%이었다. Accurately weigh 1 g of the Gilt-X extract obtained in Example 1, place in an Erlenmeyer flask, dissolve in 60 ml of water, transfer to a separatory funnel, wash with 60 ml of ether, and extract the water layer three times with 60 ml of saturated butanol. Combine all the extracts and wash with 50 ml of water. The water-saturated butanol layer was transferred to a concentrated flask made in advance, concentrated under reduced pressure, dried at 105 ° C. for 20 minutes, cooled in a desiccator for 30 minutes, and weighed to obtain the amount of irradiated saponin according to the following formula. The amount of irradiationponin measured according to the above method was 1.33%.
조사포닌 함량(w/w) % = (A-B)/S ×100Irradiated Ponin Content (w / w)% = (A-B) / S × 100
A : 물포화 부탄올층을 농축건조한 후의 플라스크 무게(g)A: Flask weight (g) after concentration-drying the water-saturated butanol layer
B : 항량으로 한 빈 플라스크 무게(g)B: Weight of empty flask in grams (g)
S : 검체의 채취량(g)S: sampling amount (g)
실시예 3Example 3
본 발명의 길경 유동엑스 추출물의 제조Preparation of the Giltung X extract of the present invention
건조 길경 11Kg을 세라믹으로 제작된 가열건조기(건조기 내용량 80리터 기준) 내에서 질소가스 10ℓ/분의 량을 사용하여 길경 표면에 분무하면서 110∼130℃에서 6시간 동안 가열 처리한 후 상기 처리한 길경을 25 v/v(%) 에탄올 80ℓ중에 넣고 7일간 초고주파 처리하여 0.45 ㎛ 제균여과기로 여과하여 길경 유동엑스 추출물 26ℓ를 수득한다.The dried path length 11Kg in a heating dryer made of ceramic (based on 80 liters of dryer content) using a nitrogen gas 10 l / min sprayed on the surface of the path length for 6 hours while heating at 110 ~ 130 ℃ for 6 hours Was added to 80 v of 25 v / v (%) ethanol and treated with ultrahigh frequency for 7 days and filtered through a 0.45 μm sterile filter to obtain 26 liters of L. extract.
실시예 4Example 4
본 발명의 길경 유동엑스 추출물에 대한 조사포닌의 함량 분석Analysis of the Content of Irradiated Phononin on the Extract of Gil-Kyung Flow of the Present Invention
실시예 3에서 수득한 길경 유동엑스 추출물 1g을 정확하게 달아 삼각플라스크에 넣고 물 60㎖에 녹여 분액깔때기에 옮기고 에테르 60㎖로 씻은 다음 물층을 물포화 부탄올 60㎖로 3회 추출한다. 추출액을 모두 합쳐서 물 50㎖로 씻는다. 물포화 부탄올층을 미리 항양으로 한 농축플라스크에 옮겨 감압농축한 후 105℃에서 20분간 건조하고 다시 데시케이트에서 30분간 식혀 무게를 달아 하기식에 따라서 조사포닌의 양을 구한다. 상기 방법에 따라서 측정한 조사포닌의 양은 3.25%이었다. Accurately weigh 1 g of the gilyeong liquid extract extracted in Example 3, place it in a Erlenmeyer flask, dissolve in 60 ml of water, transfer to a separatory funnel, wash with 60 ml of ether, and extract the water layer three times with 60 ml of saturated butanol. Combine all the extracts and wash with 50 ml of water. The water-saturated butanol layer was transferred to a concentrated flask made in advance, concentrated under reduced pressure, dried at 105 ° C. for 20 minutes, cooled in a desiccator for 30 minutes, and weighed. The amount of irradiationponin measured according to the above method was 3.25%.
조사포닌 함량(w/w) % = (A-B)/S ×100Irradiated Ponin Content (w / w)% = (A-B) / S × 100
A : 물포화 부탄올층을 농축건조한 후의 플라스크 무게(g)A: Flask weight (g) after concentration-drying the water-saturated butanol layer
B : 항량으로 한 빈 플라스크 무게(g)B: Weight of empty flask in grams (g)
S : 검체의 채취량(g)S: sampling amount (g)
상기 실시예 및 실험예를 통하여 상술한 바와 같이 본 발명은 건조 길경을 세라믹으로 제작된 가열건조기내에서 질소가스를 사용하여 분무하면서 110∼130℃에서 가열 처리한 후 에탄올 중에서 초고주파 처리하여 제균여과기로 여과하여 고함량의 조사포닌이 함유된 길경 추출물을 효율적으로 생산할 수 있다.As described above through the above examples and experimental examples, the present invention is heated to 110 to 130 ° C. while spraying dry road paths using nitrogen gas in a heat dryer made of ceramic, followed by ultrahigh frequency treatment in ethanol. By filtration, it is possible to efficiently produce a gilyeong extract containing a high content of irradiated phononine.
도 1은 본 발명 길경 추출물의 제조방법에 관한 공정도를 도시한 것이다.Figure 1 shows a process diagram for the production method of the present invention Gilyeong extract.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0076224A KR100513162B1 (en) | 2001-12-04 | 2001-12-04 | The method of manufacturing of the extract from the Platycodon grandiflorum A. DC |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0076224A KR100513162B1 (en) | 2001-12-04 | 2001-12-04 | The method of manufacturing of the extract from the Platycodon grandiflorum A. DC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030045488A KR20030045488A (en) | 2003-06-11 |
| KR100513162B1 true KR100513162B1 (en) | 2005-09-07 |
Family
ID=29572914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2001-0076224A KR100513162B1 (en) | 2001-12-04 | 2001-12-04 | The method of manufacturing of the extract from the Platycodon grandiflorum A. DC |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100513162B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100644239B1 (en) * | 2005-04-22 | 2006-11-10 | 주식회사 장생도라지 | Manufacturing method of old red platycodon and old red platycodon |
| KR102347243B1 (en) * | 2021-02-22 | 2022-01-05 | 주식회사 더가든오브내추럴솔루션 | Composition for anti-virus comprising Quillaia saponaria |
| KR102598905B1 (en) * | 2021-02-22 | 2023-11-07 | 주식회사 더가든오브내추럴솔루션 | Deodorant composition comprising Quillaia saponaria |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000002041A (en) * | 1998-06-16 | 2000-01-15 | 이은방 | Platycodi radix extract having anti-inflammatory activation |
| KR20000007345A (en) * | 1998-07-02 | 2000-02-07 | 이영춘 | Medicine of extract from long aged platycodon grandiflorum(korean name "doraji") |
| KR20010038802A (en) * | 1999-10-27 | 2001-05-15 | 박명규 | Manufacturing for Preparing the High Quality Red Ginseng |
| KR20010070531A (en) * | 2001-02-21 | 2001-07-25 | 이세복 | Whitening cosmetic material containing an extract of natural Phellinus Linteus |
-
2001
- 2001-12-04 KR KR10-2001-0076224A patent/KR100513162B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000002041A (en) * | 1998-06-16 | 2000-01-15 | 이은방 | Platycodi radix extract having anti-inflammatory activation |
| KR20000007345A (en) * | 1998-07-02 | 2000-02-07 | 이영춘 | Medicine of extract from long aged platycodon grandiflorum(korean name "doraji") |
| KR20010038802A (en) * | 1999-10-27 | 2001-05-15 | 박명규 | Manufacturing for Preparing the High Quality Red Ginseng |
| KR20010070531A (en) * | 2001-02-21 | 2001-07-25 | 이세복 | Whitening cosmetic material containing an extract of natural Phellinus Linteus |
Non-Patent Citations (2)
| Title |
|---|
| Ultrasonics Sonochemistry, 8(4), 347-52 (2001. 10 * |
| 한국식품과학회지, 23(6), 673-6 (1991 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030045488A (en) | 2003-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Citri Reticulatae Pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine | |
| Fu et al. | Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi) | |
| Chen et al. | A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L.(coltsfoot) | |
| Küpeli et al. | Flavonoids with anti-inflammatory and antinociceptive activity from Cistus laurifolius L. leaves through bioassay-guided procedures | |
| AU2002348988A1 (en) | Composition comprising Wenguanguo extracts, methods for preparing same and uses thereof | |
| WO2003017919A2 (en) | Composition comprising wenguanguo extracts, methods for preparing same and uses therof | |
| WO2004052383A1 (en) | An composition containing triterpenoid saponins extracted from bamboo, and the preparation method and use thereof | |
| Gong et al. | The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control | |
| CN104138420B (en) | A kind of processing method of Herba Cistanches medical material | |
| KR102115669B1 (en) | Preparation method of black Platycodon grandiflorus having increased crude saponin and reduced Platycodin D, inhibiting production of benzopyrene | |
| CN107550965A (en) | A kind of preparation method of Folium Artemisiae Argyi extract | |
| CN107913299A (en) | A kind of extraction preparation method of high pulmonary fibrosis resistant activity snow ganoderma lucidum total flavones | |
| LEE et al. | Current perspectives on Chinese medicines and dietary supplements in China, Japan and the United States | |
| WO2016117705A1 (en) | Agent for inducing production of hepatocyte growth factor | |
| KR100513162B1 (en) | The method of manufacturing of the extract from the Platycodon grandiflorum A. DC | |
| CN1104906C (en) | Tibetan-medicinal bath for treating rheumatism and its preparing process | |
| Wang et al. | Polysaccharides from fructus corni: Extraction, purification, structural features, and biological activities | |
| CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes | |
| Luo et al. | Botany, phytochemistry, pharmacologic activities, traditional applications, pharmacokinetics, quality control and toxicity of Zanthoxyli Radix: an updated review | |
| CN108815357B (en) | A Chinese medicinal composition with antipyretic effect, and its preparation method | |
| CN107308270A (en) | A kind of anticancer pharmaceutical composition | |
| Lau et al. | Anti-Diabetic Effects of Edgeworthia chrysantha and Edgeworthia gardneri Flower Buds –An Ethnic Herbal Tea in China | |
| CN106266876A (en) | A kind of for compound ointment treating eczema and preparation method thereof | |
| Kabir et al. | In vitro Study of Antioxidant Potentials, and Thrombolytic Activity of the Leaves of Delonix regia (Family: Fabaceae) | |
| CN105663429A (en) | Medicine for treating vesicular beriberi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| AMND | Amendment | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120711 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130620 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140829 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150828 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160816 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20180830 Year of fee payment: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20190828 Year of fee payment: 15 |